Building on the success of our 2017 meeting, Global Engage is pleased to announce the **4th Biologics & Biosimilars Congress** which will be held on the 5th and 6th March, 2018 in Berlin, Germany. The conference will host over 60 expert speakers and panellists in three tracks across both days, and is expected to attract over 250 attendees and 30 poster presentations. The conference is part of Global Engage’s successful Drug Discovery series which includes our Precision Medicine, Medicinal Chemistry and Synthetic Biology congresses.

Attracting industry, regulatory and academic experts working in all areas of antibody, protein and biosimilar research, the two-day meeting will explore a variety of topics across three tracks. With a strong focus on antibody based therapeutics, tracks 1 and 2 provide industry leaders with the opportunity to present updates on their strategy, pipeline and existing candidates in a variety of areas including antibody discovery and design, immuno-oncology, bispecific antibodies and antibody-drug conjugates. Other talks in these tracks will examine checkpoint inhibitor therapies and recent innovations in the exciting area of T-Cell therapeutics. Track 3 looks to cover developments in fusion proteins, novel scaffolds and immunogenicity considerations across protein biotherapeutics. The Biosimilars track explores themes of similarity, regulation and public perception, alongside presentations on candidate generics in various stages of development. Executive panels and roundtables will foster discussion on the direction of the field, and the approaches required to ensure that the industry continues to flourish.

This two-day interactive meeting will allow you the opportunity to keep up to date with cutting edge strategies, technologies and the latest research, as well as potential to keep abreast of your competitors through access to renowned solution providers, and to make lasting connections with other thought leaders, experts, businesses and entrepreneurs in your field.
**DAY 1 – TRACK 1**

**Antibody Based Therapeutics: discovery and design**
- Case study - multispecific antibodies
- Case study - treatments across the blood-brain barrier
- Case study – antibody discovery and optimization
- Panel Discussion – developing antibody therapeutics
  - strategies, techniques and challenges

**DAY 1 – TRACK 2**

**Antibody-Drug Conjugates: design, stability optimization, linker and payload development**
- Case study - amanitin based ADCs
- Case study - fragment antibody-drug conjugates
- Case study – novel carriers, linker and payloads

**DAY 1 – TRACK 3**

**Biosimilars: design and optimization, commercialization strategies, quality control, IP and regulatory issues**
- Case study - litigation studies
- Case study - global regulation trends
- Case study - patient-clinic relations
- Case study – bringing biosimilars to the commercial market
- Panel discussion – progress in the regulatory landscape for biosimilars

**DAY 2 – TRACK 1**

**Immunotherapy**
- Case study - bispecific t-cell engagers
- Case study - solid tumour immunotherapies
- Case study - checkpoint blockades
- Panel discussion - the impact of bispecific antibodies on oncology and challenges in developing novel cancer treating biologics

**DAY 2 – TRACK 2**

**Antibody-Drug Conjugates: case studies**
- Panel Discussion – Reviewing the progress of Antibody-Drug Conjugates and the next steps in ADC design

**T-cell immuno-oncology**
- Case study - conjugating cytokines for increasing tumor-targeting t-cell generation

**DAY 2 – TRACK 3**

**Protein biotherapeutics: alternative scaffolds, fusion proteins, immunogenicity, protein expression**
- Case study - alternative scaffolds
- Case study - fusion proteins
- Case study – immunogenicity

---

**ROUNDTABLE SESSIONS**

**Session 1: Biological Therapeutics**
- Table 1: Safety and efficacy of biologic therapeutics
- Table 2: Immunogenicity considerations
- Table 3: Antibody discovery techniques
- Table 4: New antibody therapeutics: bi- and multispecifics
- Table 5: Discovery and development of antibodies against benign inflammatory diseases
- Table 6: ADC optimisation

**Session 2: Biosimilars**
- Table 1: Patient access and pricing
- Table 2: Patient and public engagement
- Table 3: Overcoming barriers to biosimilar adoption
- Table 4: Strategies for addressing Intellectual Property barriers
**Gold Sponsors**

- eurofins DiscoverX
- RTC
- SCHRÖDINGER
- CHEMICAL COMPUTING GROUP
- dynamic BIOSENSORS

**Other Exhibitors & Content Sponsors**

- Axonlab
- YUMAB
- ridgeview instruments AB
- Bio-Works
- UGA Biopharma
- ProBioGen
- Agilent Technologies
- KBI Biopharma
- Biokal
- SERVA
- DNAlytics
- Fair Journey Biologics
- BioGenes
- BioPharmaSpec
- SYNENTEC
- chemometec
<table>
<thead>
<tr>
<th>CONFIRMED SPEAKERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>VOLKER SCHELLENBERGER</td>
</tr>
<tr>
<td>CEO and President, Amunix</td>
</tr>
<tr>
<td>ROLAND BUELOW</td>
</tr>
<tr>
<td>CEO, TeneoBio</td>
</tr>
<tr>
<td>ANDREAS PAHL</td>
</tr>
<tr>
<td>CSO, Heidelberg Pharma</td>
</tr>
<tr>
<td>JENS NIEWOEHRNER</td>
</tr>
<tr>
<td>Group Leader, Roche</td>
</tr>
<tr>
<td>GOKHAN YAHIOGLU</td>
</tr>
<tr>
<td>Director of Chemistry, Co-founder, Antikor</td>
</tr>
<tr>
<td>SENIOR REPRESENTATIVE Yumab</td>
</tr>
<tr>
<td>TANVIR TABISH</td>
</tr>
<tr>
<td>Head of Drug Product Development for Gene Therapy and Coagulation Factors, Shire</td>
</tr>
<tr>
<td>CATHERINE HUTCHINGS</td>
</tr>
<tr>
<td>Consultant, Heptares</td>
</tr>
<tr>
<td>TREVOR HALLAM</td>
</tr>
<tr>
<td>CSO, Sutro Biopharma</td>
</tr>
<tr>
<td>PHILIP HOWARD</td>
</tr>
<tr>
<td>Founder &amp; CSO, Spirogen</td>
</tr>
<tr>
<td>MARTIN STEEGMAIER</td>
</tr>
<tr>
<td>Head Discovery &amp; Site Head Large Molecule Research, Pharma Research &amp; Early Development, Roche Innovation Center Munich</td>
</tr>
<tr>
<td>SEEMA KUMAR</td>
</tr>
<tr>
<td>Associate Director, Merck KGaA</td>
</tr>
<tr>
<td>JENNY THIRLWAY</td>
</tr>
<tr>
<td>Technical Director, Glythera</td>
</tr>
<tr>
<td>KARL ANDERSSON</td>
</tr>
<tr>
<td>CEO, Ridgeview</td>
</tr>
<tr>
<td>STEPHAN FISCHER</td>
</tr>
<tr>
<td>CEO, MAB Discovery</td>
</tr>
<tr>
<td>LISA MUELLER</td>
</tr>
<tr>
<td>Partner and Chair of the Life Science Group, Michael Best &amp; Friedrich LLP</td>
</tr>
<tr>
<td>GRZEGORZ ORLIK</td>
</tr>
<tr>
<td>Head of Medical Affairs, Biosimilars and Generics Europe, Accord Healthcare</td>
</tr>
<tr>
<td>CHRISTIAN MAASCH</td>
</tr>
<tr>
<td>Managing Consultant RA CMC/Biotech, Xendo Deutschland Gmbh</td>
</tr>
<tr>
<td>HITTO KAUFMANN</td>
</tr>
<tr>
<td>Global Vice President Biopharmaceuticals, Sanofi</td>
</tr>
<tr>
<td>VIBHA JAWA</td>
</tr>
<tr>
<td>Director Biologics and Vaccines, Merck Sharp &amp; Dohme</td>
</tr>
<tr>
<td>AMRIK BASRAN</td>
</tr>
<tr>
<td>CSO, Avacta</td>
</tr>
<tr>
<td>TIMOTHY LOWINGER</td>
</tr>
<tr>
<td>CSO, Mersana</td>
</tr>
<tr>
<td>MATHIEU CINIER</td>
</tr>
<tr>
<td>CSO, Affilogic</td>
</tr>
<tr>
<td>SLAVOLJUB MILOSEVIC</td>
</tr>
<tr>
<td>Head of Technology Innovation, Medigene</td>
</tr>
<tr>
<td>SEEMA KUMAR</td>
</tr>
<tr>
<td>Associate Director, Merck KGaA</td>
</tr>
<tr>
<td>BERNHARD SCHLIERETH</td>
</tr>
<tr>
<td>Senior Director, Non-clinical safety, Covagen</td>
</tr>
<tr>
<td>ROMAN IVANOV</td>
</tr>
<tr>
<td>Vice President, Research &amp; Development, Biocad</td>
</tr>
<tr>
<td>OLIVER HILL</td>
</tr>
<tr>
<td>Vice President, APOGENIX AG</td>
</tr>
<tr>
<td>ARMIN SEPP</td>
</tr>
<tr>
<td>Associate Fellow, GSK</td>
</tr>
<tr>
<td>SYD JOHNSON</td>
</tr>
<tr>
<td>Vice President, MacroGenics</td>
</tr>
<tr>
<td>ANNICK DE VRIJES</td>
</tr>
<tr>
<td>Head Diagnostics (Biologics), Sanquin Bloedvoorziening</td>
</tr>
<tr>
<td>BORIS GOROVITS</td>
</tr>
<tr>
<td>Senior Director, Pfizer</td>
</tr>
<tr>
<td>PAUL WASSMANN</td>
</tr>
<tr>
<td>Principal Scientist, Novartis</td>
</tr>
<tr>
<td>NIGEL TEMPERTON</td>
</tr>
<tr>
<td>Senior Lecturer and Joint Head, Viral Pseudotype Unit, University of Kent</td>
</tr>
<tr>
<td>ANGUS DALGLEISH</td>
</tr>
<tr>
<td>Professor of Oncology, St George’s University of London</td>
</tr>
<tr>
<td>BARBARA VALSASINA</td>
</tr>
<tr>
<td>Project and Group Leader, Nerviano Medical Sciences</td>
</tr>
<tr>
<td>JILL CARTON</td>
</tr>
<tr>
<td>Director, Biologics Discovery Janssen BioTherapeutics, Janssen R&amp;D</td>
</tr>
</tbody>
</table>

4TH BIOLOGICS & BIOSIMILARS CONGRESS EUROPE 2018
CONGRESS SCHEDULE

DAY 1 MONDAY 5TH MARCH 2018

08:00-08:50 Registration & Refreshments

08:50-08:55 Global Engage Welcome Address

08:55-09:00 OPENING ADDRESS: SENIOR REPRESENTATIVE
Chemometec

09:00-09:35 KEYNOTE ADDRESS:
VOLKER SCHELLENBERGER
CEO and President, Amunix
ProTIA – Bispecific T cell engagers designed for local activation in the tumor environment
• ProTIAs are highly potent bispecific T cell engagers
• ProTIAs are administered to patients as inactive long half-life prodrugs
• Activation by tumor-associated proteases occurs within tumor tissue
• The released active form has a short circulation half-life to minimize the risk of systemic exposure
• Amunix’ proprietary XTEN™ protein polymer provides half-life modulation, masking of binding sites, and facilitates manufacturing of ProTIA prodrugs

09:35-10:10 SOLUTION PROVIDER PRESENTATION:
SENIOR REPRESENTATIVE
Schrödinger GmbH
Title TBC

10:10-10:40 SOLUTION PROVIDER PRESENTATION:
ALEXANDER BAUMANN
European Sales & Technical Support Director, DiscoverX
Seamless Integration of Robust Bio Assays from Development to QC Lot release of Biologics
A quantitative and robust bioassay that is reflective of the MOA of the drug is a critical component of any development program. We have expanded our PathHunter® cell-based assay platform to provide simple bioassays for potency determination and stability testing of biological drugs. These quantitative and robust assays rely on the native biology of the relevant receptor, allowing developers to choose a readout that is truly reflective of the MOA of their drug. Importantly, these are homogeneous assays that use "thaw-and-use" cryopreserved cells and simple protocols to minimize assay variability compared to traditional assays, and are highly scalable and suitable for automation. We will share case studies from our large portfolio of qualified bioassays for several different biosimilar and immuno-oncology targets.

10:40-11:50 Morning Refreshments / Poster Presentations / One-to-One Partnering Meetings
**ANTIBODY-BASED THERAPEUTICS**

**ROLAND BUELOW**  
CEO, TeneoBio  
Multi-specific antibodies for human therapy  
TeneoBio, Inc. is developing a new class of therapeutics, Human Heavy Chain Antibodies (UniAbs™). The high affinity and robust function of UniAbs combine antibody specificity with excellent developability. The UniAbs’ fully human VH domains, UniDabs™, are versatile building blocks for the development of therapeutics with multi-specificity. TeneoBio’s antibody discovery engine is based on UniRat™, a proprietary human heavy chain only, transgenic rat. For antibody discovery we apply a novel sequence-based discovery approach using NGS, bioinformatics and high-throughput recombinant protein expression. We developed multivalent antibodies with superior tumor cell cytotoxicity and specificity including UniAbs targeting CD38 and PD1 and T-cell engaging antibodies targeting BCMA on plasma cells. Our results demonstrate that UniDabs are versatile building blocks for the generation of multi-valent therapeutics with superior potency and specificity.

**JENS NIEWOEHNER**  
Group Leader, Roche  
Effector functions of Brain Shuttle antibody therapeutics  
- Transport of therapeutic antibodies into the brain using Brain Shuttle technology  
- Safety aspects of Brain Shuttle molecules with Fc effector function  
- Choosing the right format for safety and efficacy

**ANTIBODY-DRUG CONJUGATES**

**ANDREAS PAHL**  
CSO, Heidelberg Pharma  
HDP-101: “ATAC” Platform: Proprietary, Amanitin-based ADC  
Applies New Mechanism for Impacting Multiple Myeloma  
- Heidelberg Pharma: First company developing RNA Polymerase II inhibitors for cancer treatment  
- Amanitin is the most effective and specific inhibitor of RNA Polymerase II  
- ATAC: ADC technology harnessed to deliver this new mode of action to cancer patients  
- ATACs kill both dividing and dormant tumor cells  
- ATACs are effective on low expressed targets  
- ATACs have a large therapeutic index and favorable tolerability, no liver toxicity  
- Deletor of p53 is a payload-specific predictive biomarker for ATACs  
- BCMA is an ideal target due to its restricted expression on malignant Multiple Myeloma cells  
- ATAC/HDP-101: ideal approach to target low expressed BCMA on slowly proliferating tumor cells  
- HDP-101: High efficacy in animal models; long-lasting remission after single treatment  
- First-in-Man starts end of 2018

**GOKHAN YAHIOGLU**  
Director of Chemistry, Co-founder, Antikor  
Not too big-not too small: Fragment Drug Conjugates (FDCs) as alternatives to ADCs for solid tumours  
Antikor is developing a proprietary platform to discover and develop FDCs for solid tumours. ADCs have failed to deliver on their early promise with over 20 clinical development trials discontinued. It is clear that one size does not fit all indications and addressing difficult solid tumours requires an alternative approach. Using smaller antibody formats is an attractive option due to their faster elimination from the circulation and enhanced tumour penetration. Antikor’s OptiLink technology where payload loading is optimised to obtain high drug-to-antibody ratio FDCs, allows the early delivery of a bigger cytotoxic “hit”. Compelling data with our scFv antibody format FDCs show:  
- Optimal PK/PD properties  
- Superior in vivo efficacy in Her2 models for breast and gastric cancer compared to the ADC  
- Rapid tumour penetration and clearance  
- Better tolerability and are less toxic than the ADC equivalent  
We believe this fast-in-fast-out approach will result in low systemic exposure and an improved TI.

**BIOSIMILARS**

**LISA MUELLER**  
Partner and Chair of the Life Science Group, Michael Best & Friedrich LLP  
Global Legal Issues Associated with Biosimilars  
This presentation will focus on:  
- The current state of biosimilars globally including the number of biosimilars currently on market in the major biosimilar “player” countries;  
- Regulatory issues and challenges faced by biosimilars globally (e.g., comparability studies, Phase III studies, interchangeability, naming requirements, etc.); and  
- Patent challenges faced by biosimilar companies including conducting a freedom-to-operate analysis in various jurisdictions to identify the relevant patents (if any) at issue, ways to minimize risk and high level review of patent litigation involving biosimilars worldwide.

**GRZEGORZ ORLIK**  
Head of Medical Affairs, Biosimilars and Generics Europe, Accord Healthcare  
Challenges in medical communication for biosimilar products  
Communication about biosimilar products changes. Some issues become less critical, but we have other emerging. Typical points cover:  
- Similarity vs. identity to reference product  
- Substitution and interchangeability  
- Safety (with special focus on autoimmunity)  
- Communication of pricing policy and access to the treatment
TREVOR HALLAM  
CSO, Sutro Biopharma  
Will Optimized Single Molecular ADC Species Set New Precedents For Clinical Performance?  
• Cell-free antibody production enables use of reactive non-natural amino acids to generate precisely positioned irreversible conjugates with high fidelity.  
• Ability to rapidly generate many variants of full length IgG species with different conjugation sites within days at quantities and quality sufficient for pharmacodynamic and toxicological assessment allows iterative design to optimize ADC performance and reduces preclinical development times by 18 months  
• We’ll provide updates on our lead clinical development candidates.

PHILIP HOWARD  
Chief Scientific Officer, Spirogen / Senior Fellow, MedImmune  
Antibody-Pyrrolobenzodiazepine Conjugates  
Dr Howard’s talk will cover the development of Pyrrolobenzodiazepine (PBD) payloads for use in Antibody Conjugates. The presentation will also give an update on the clinical progress of Antibody PBD Conjugates.
SOLUTION PROVIDER PRESENTATION:

DANIELA TEIXEIRA
COO, Fairjourney Biologics

The journey to "the" antibody: accessing a versatile toolbox

Fairjourney Biologics, an established company with an outstanding track record of biotech and Big pharma partners, offers a range of assets and services on antibody engineering, discovery and production. Being a profitable biotech company, Fairjourney Biologics has implemented a co-development and R&D arm to complement its fee-for-service main unit. The company has developed a full suite of primers for generation of antibody libraries from different species and has validated various naïve human Fab and llama VHH phage display libraries. Fairjourney Biologics has one of the biggest in the world antibody discovery teams available to partner and it has entered into agreements with academia, biotech companies and Big pharma to systematically explore ground breaking targets and creating new ventures.

---

SEEMA KUMAR
Associate Director, Merck KGaA
ADC Bioanalytical Strategies: PK Assay Continuity Between Discovery and Development

Depending on the PK question that needs to be answered, the strategies and bioanalytical approaches employed for ADC assay development may need to be adapted. At the discovery stage, due to the limited availability of critical reagents, time and resources, flexible “fit-for-purpose” assays are often employed. On the contrary, the late stage non-clinical drug development typically requires qualified and validated assays. The differences in critical reagents and assay formats/platforms adopted at different stages of drug development may impact the observed analyte concentration and the associated PK profile/parameters. However by applying rational scientific understanding of what each assay format and assay reagent is measuring, an appropriate interpretation of observed data can be made. Case studies on assay continuity during various stages of non-clinical development of ADC (Discovery to Development) will be presented.

---

ANNICK DE VRIES
Head Diagnostics (Biologics), Sanquin Bloedvoorziening

Serum level measurements for biologics/biosimilars: real life data

• Experience from routine diagnostics on PK and ADA measurements
• One dos/multitude of serum levels; impact of immunogenicity on PK
• Validation of PK/ADA setup for originators for biosimilars

---

For sponsorship opportunities please contact Nick Best/Gavin Hambrook at sponsorship@globalengage.co.uk

---

For sponsorship opportunities please contact Nick Best/Gavin Hambrook at sponsorship@globalengage.co.uk
Barbara Valsasina
Project and Group Leader, Nerviano Medical Sciences
NMS ADC platform: focus on Thienoindoles, a novel class of potent toxins highly suitable for ADC generation
• ADC platform at NMS.
• The toxin NMS-P528 and the corresponding drug-linker NMS-P945, optimized members of the thienoindole class, highly suited for conjugation with targeted antibodies due to their favourable physicochemical properties.
• Preclinical in vitro and in vivo obtained results with selected model antibodies bearing NMS-P945 drug linker.

Claire Dobson
Associate Director, Antibody Discovery and Protein Engineering, MedImmune
Engineering pH dependent antigen binding antibodies to overcome target mediated clearance in vivo
• Antibodies targeting membrane bound antigens with a high rate of synthesis are rapidly eliminated from plasma by antigen mediated clearance, thus compromising their therapeutic utility.
• We describe a protein engineering approach to create a pH dependent antigen binding antibody directed to a GPCR. The antibody binds to its antigen in plasma (pH7.4) and following endocytosis dissociates from the antigen in the acidic endosome (pH5.8).
• The antigen is subsequently degraded by proteolysis in the lysosome and the antibody is recycled back to the cell surface via FcRn enabling it to bind to another antigen.
• The resulting antibody has an extended half-life in vivo and its efficacy is not limited by dose.

Jenny Thirlway
Technical Director, Glythera
Assessing the therapeutic efficacy of novel toxins conjugated using the stable PermaLink® technology
Antibody Drug Conjugates (ADCs) are an emerging class of targeted therapeutics with the potential to improve therapeutic index over traditional chemotherapy. By combining the targeting power of antibodies with the cell killing capability of potent cytotoxic molecules, it is possible to kill cancer cells more effectively whilst reducing debilitating side effects. Glythera’s PermaLink® technology has been validated in a range of ADC models and demonstrated improved stability, efficacy and tolerability profiles. Using these important differentiators Glythera has accessed a portfolio of toxins with known and novel modes of action and has completed the three part ADC jigsaw by additionally accessing novel antibodies through its partners.

Invitation Out
MARTIN STEEGMAIER
Head Discovery & Site Head Large Molecule Research, Pharma Research & Early Development, Roche Innovation Center Munich

Pioneering antibody technology – Advancing transformative cancer immunotherapy agents

- Therapeutic efforts to engage the immune system against cancer has generated exciting breakthroughs and clinically meaningful benefit to a subset of patients. New bi- and multi-specific antibodies are now in various phases of clinical development and will become the next generation of antibody-based therapies.
- We have generated a portfolio of T cell bispecific antibodies and novel, engineered targeted immune-modulators that show promising pre-clinical and clinical activity as single agent or in combination with other cancer immunotherapy agents.
- The CrossMAb technology has proven to be very versatile, allowing the generation of various bispecific antibody formats providing great opportunity to tackle novel biology and to convey superior efficacy.
- Examples will be given how antibody format fundamentally influences the mode of action and activity of these novel immunotherapy agents.

RONDOUTABLE DISCUSSIONS:

Table 1: Patient access and pricing
Table 2: Patient and public engagement
Table 3: Overcoming barriers to biosimilar adoption
Table 4: Strategies for addressing Intellectual Property barriers

SOLUTION PROVIDER PRESENTATION:

ULRICH RANT
CEO, Dynamic Biosensors GmbH

Biophysical characterization of bispecific antibodies of dual-targeting specificity

The measurement of binding rates and avidity effects in the simultaneous engagement of two antigens by a bispecific antibody is key for optimizing target specificity early in the development process. I will describe the utilization of the switchSENSE® biosensor to emulate the display of two different target antigens on a cancer cell surface. Precise control of the relative abundance and spatial arrangement of two antigen species on the sensor is achieved using DNA-guided surface functionalization and dual-color fluorescence detection. The quantitative analysis provides insight on how to adjust the individual affinities of the bispecific antibody arms, so that most favorable conjoint action is achieved, i.e., maximal on-target and minimal off-target binding, respectively.
**PANEL DISCUSSION:** The impact of bispecific antibodies on oncology and challenges in developing novel cancer treating biologics  
**ROLAND BUELOW**  
CEO, TeneoBio  
Invitation Sent to Senior Representatives x3

**PANEL DISCUSSION:** Reviewing the progress of Antibody-Drug Conjugates and the next steps in ADC design  
**TIMOTHY LOWINGER**  
CSO, Mersana  
Pre-clinic to clinical trial case study – Title TBC  
Invitation Sent to Senior Representatives x4

---

**AMRIK BASRAN**  
CSO, Avacta  
Affimer Therapeutics: A novel Protein Scaffold for Modulating Checkpoint Inhibitors  
Affimer therapeutics are based on the human protein Stefin A, a small (12kDa) intracellular protease inhibitor. We have used phage display to identify molecules that bind to PD-L1 with single digit nM affinity and compete for the PD-1/CD80 epitope. The Affimer protein was also shown to compete against Atezolizumab for PD-L1. The Affimer scaffold is amenable to formatting as a genetic fusion with the Fc region of an antibody and is expressed transiently at high levels from HEK293 cells. We have also demonstrated PK and efficacy in a mouse syngeneic model using a surrogate tool Affimer protein.

**MATHIEU CINIER**  
CSO, Affilogic  
The use of the Nanofitin alternative scaffold as a versatile platform for radioimaging and drug conjugate: a case study with anti-EGFR Nanofitins cross-reacting on both the human and murine EGFR  
Key advantages of the Nanofitin technology as a vector for radioimaging  
- Possibility to tailor the selection to obtain cross-reactive Nanofitin  
  - Better significance of the preclinical studies in murine model in term of biodistribution  
  - Fast systemic clearance  
  - Compatible with fast decaying radio-isotope  
  - Simple radioactive waste handling  
  - Better patient compliance  
  - Higher production capacity  
- No cysteine – regioselective conjugation allowed  
- High stability – ease of chemical conjugation  
- No accumulation in healthy organ
**Table 1: Safety and efficacy of biologic therapeutics**
- Enabling precise interaction analysis of biologicals and bispecifics interacting with cell-surface receptors on living cells with LigandTracer
- Using detailed binding data to decipher underlying biology and support mode of action determinations
- Selecting binders based on clear and highly repeatable binding characteristics obtained relevant, cell-based environment

**Table 2: Immunogenicity considerations**

**Table 3: Antibody discovery techniques**

**Table 4: New antibody therapeutics: bi- and multispecifics**

- High tumor to blood ratio at short time frame
- Key advantages of the Nanofitin technology as a vector for drug conjugate
- Small scaffold – high tissue penetration
- Fast clearance can be tuned to allow longer resilience via proprietary half life extension technology
- Examples will be given of the versatility of the scaffold
  - Can be easily conjugated to payload via chemical conjugation or genetic fusion (immunotoxin, immuno enzyme)
  - Can be conjugated to Nanoparticle

For sponsorship opportunities please contact Nick Best/Gavin Hambrook at sponsorship@globalengage.co.uk

**Balancing Colloidal and Conformational Stability Factors in Biological Formulation Selection**

The long-term stability of a protein therapeutic formulation is key to its viability as a drug product. A significant challenge during protein formulation development is the generation and interpretation of data that is predictive of long-term stability. While chemical stability of the API may be important for long-term product quality, it is the assessment of physical stability that typically allows discrimination amongst protein formulations. For many biologicals, prediction of physical stability involves balancing countervailing impacts of conformational and colloidal stability. At this presentation, we will link the theoretical aspects of molecular stability to the approaches and tools used by KBI Biopharma BVBA for biologicals formulation development.
Immunogenicity of novel biotherapeutics is a major hurdle in drug development. Here, we report on the immunogenicity of a novel bispecific antibody construct (TNFα/IL-17 dual cytokine inhibitor) for the treatment of inflammatory diseases. Interestingly, our data indicate that the immunogenicity is a consequence of dual target engagement and target structure rather than the intrinsic characteristics of the bispecific antibody construct.

Emerging role of ADCs in non-oncological therapeutic areas

Case study: Generation of ADC against T. brucei, parasite causing sleeping sickness

We have studied the tissue distribution and elimination kinetics of 89Zr-labelled albumin-binding domain antibody (AlbudAb) in healthy human volunteers. Extended plasma half-life was observed and combined with PET imaging data which indicated rapid initial tracer distribution in the vasculature followed by gradual tissue-dependent penetration which will be analyzed by physiologically-based pharmacokinetic (PBPK) modeling. Albumin-like plasma PK suggests that AlbudAbs can be useful for increasing and modulating the exposure of therapeutic payloads attached to the molecule.
DAY 2 TUESDAY 6TH MARCH 2018

CONGRESS SCHEDULE

16:00-16:35
DEBORAH CHARYCH
Executive Director, Nektar Therapeutics
Harnessing potent cytokine pathways for immuno-oncology and beyond

16:10-16:35
PAUL WASSMANN
Principal Scientist, Novartis
An analytical tool-box enabling efficient lead candidate selection during Developability Assessment of Therapeutic Proteins

16:00-16:35
WILL GOUNDRY
Associate Principal Scientist, AstraZeneca
Challenges and Opportunities in the Synthesis of ADC Payloads
- An overview of ADC payloads currently in development
- A detailed discussion of AstraZeneca’s payloads
- What challenges should you consider when scaling up the synthesis of an ADC payload?
- A case study for the scale-up of AstraZeneca’s Tubulysin payload
- Future perspective: what are the opportunities for new payloads

16:35-17:00
No Presentation in this Track

16:35-17:00
CHRISTIAN MAASCH
Managing Consultant
RA CMC/Biotech, Xendo Deutschland GmbH
Biophysical methods to take center stage in orthogonal analytics for comparability exercises and quality tasks of biologics

17:00
Conference Close
MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of €100 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.
Maritim proArte Hotel Berlin,
Friedrichstrasse 151,
10117 Berlin, Germany

Our Maritim proArte Hotel Berlin lies on Friedrichstrasse, one of Berlin's main thoroughfares. In addition to the modern furnishings of your well appointed hotel room, you can enjoy free Wi-Fi. Refined marble bathrooms underscore the stylish ambience of your hotel room. The maritime design of the swimming pool and wellness area is a blessing to body and soul during your Berlin stay. In our trendy "berlin tapas" restaurant you can satisfy your appetite with Berlin specialities in canapé style. Enjoy a diverse range of breakfast treats every day in the Galerie restaurant. As the largest conference hotel in Central Berlin, you can rely on our expert support for your event, whether large or small. The splendid "Unter den Linden" street is a stone's throw away. Sightseeing, meetings, shopping or cultural experiences – at the Maritim proArte Hotel Berlin you right in the midst of the action.